Relmada Therapeutics
RLMD
87 hedge funds and large institutions have $263M invested in Relmada Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 13 closing their positions.
606% more call options, than puts
Call options by funds: $5.55M | Put options by funds: $785K
200% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 12
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2% more funds holding
Funds holding: 85 → 87 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.79% less ownership
Funds ownership: 59.19% → 57.4% (-1.8%)
17% less capital invested
Capital invested by funds: $316M → $263M (-$53.7M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$11.3M |
| 2 |
Millennium Management
New York
|
+$6.38M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$5.35M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.83M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$3.33M |
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$29.9M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$7.48M |
| 3 |
BlackRock
New York
|
-$6.96M |
| 4 |
TA
Tiedemann Advisors
New York
|
-$1.78M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$1.55M |
RLMD Hedge Fund Activity: Q3 2021 in Review
87 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2021, worth a combined $263M — down 17% from $316M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RLMD positions and 13 closed out — a net gain of 2 holders — while 36 added to existing stakes and 12 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $11.3M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $29.9M sold.
- 87 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2021, up from 85 in Q2 2021.
- Funds reported $263M of Relmada Therapeutics stock for Q3 2021, down 17% quarter-over-quarter.
- 15 funds opened new Relmada Therapeutics positions in Q3 2021 and 13 closed out, a net change of +2 holders.
- The largest Relmada Therapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $11.3M added.
- The largest Relmada Therapeutics seller in Q3 2021 was Avoro Capital Advisors, an estimated $29.9M sold.
Based on aggregated 13F filings for Q3 2021.